Oncology
Areas of Partnering Interest
- Novel Targets or Agents
- Angiogenesis
- Signal transduction
- Immunotherapy
- Cytotoxics and potentiators
- Anemia and inflammation
- Cancer Stem Cells
- For novel target identification and translatable in vivo models
- Cancer Vaccines
Predictive In Vivo Models - Resistant to anti-VEGF therapies
- More correlative with clinical outcome
- Compatible with combination studies
- Immune enhancement approaches
- Molecular Profiling
- To identify targets
- To validate pre-clinical models
- To match the right drug to the right patient
- To map disease progression for high priority tumors
- Systems Biology Software Tools & Databases
"Pfizer is committed to flexible, transparent and mutually beneficial long-term relationships with its partners. By joining forces, we can bring quality therapies to patients worldwide. Let's work together for a healthier world."
—Bill Ringo, Senior Vice President,
Worldwide Business Development
Strategy & Innovation
- Contact Us
- Investors
- Sitemap
- Careers
- Business to Business
- Terms of Use
- Global Network
- Privacy Policy
Copyright © 2002–2009 Pfizer Inc. All rights reserved. This information is intended only for residents of the United States. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. Pfizer Inc is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.
